Ohio pharmacy board reverses ban on hydroxychloroquine after GOP Gov. DeWine’s request
COLUMBUS, Ohio – The State of Ohio Board of Pharmacy has changed course on its ban of hydroxychloroquine and chloroquine as coronavirus treatments following the governor’s urging to do so.
Beginning Thursday, pharmacies, clinics and other medical institutions were to be prohibited from dispensing or selling the drugs to treat COVID-19, according to regulations issued by the State of Ohio Board of Pharmacy. They could still be used in clinical trials, said Cameron McNamee, director of policy and communications for the board.
That regulation change has since been pulled back by the board though. Instead, the board now plans to re-examine the issue with the assistance of the State Medical Board of Ohio, clinical experts, and other stakeholders to determine its next steps, according to an announcement.
The board’s shift came after Republican Gov. Mike DeWine asked the state pharmacy board on Thursday morning to rescind its plan to ban hydroxychloroquine and chloroquine as treatments for the virus.
'America's Frontline Doctors':May be real doctors, but experts say they don't know what they're talking about
DeWine says treatment should be doctor-patient decision
DeWine said the decision of how to treat COVID-19 should instead be between patients and their doctors.
“The Board of Pharmacy and the State Medical Board of Ohio should revisit the issue, listen to the best medical science, and open the process up for comment and testimony from experts,” DeWine said in a prepared statement.
Hydroxychloroquine has been touted by President Donald Trump despite medical studies showing the drug to be ineffective at treating the disease. The drug may also cause serious cardiac side effects, according to the Food and Drug Administration.
Ohio speaker Householder indicted in federal bribery case:Title stripped in 90-0 vote
The U.S. Food and Drug Administration in mid-June revoked an emergency authorization for hydroxychloroquine that had allowed it to be used to treat COVID-19 patients. Despite the FDA’s revocation and until now, it could technically still be used for off-label treatment of the virus in Ohio, McNamee said.
“Basically, it’s a patient safety issue,” McNamee said on Wednesday before DeWine’s request and the board’s subsequent reversal. “We’re looking at the best science to determine what’s best for the patients of Ohio.”
Under the regulation, pharmacists in Ohio found to be selling or dispensing the drug to treat COVID-19 could have faced disciplinary action ranging anywhere from a warning or fine to a temporary suspension of their license. That action would have depended on the situation, McNamee said Wednesday.
“The long and short of it is, we want people to focus on what works, such as social distancing and mask use,” McNamee said. “We ultimately want to make sure people are being safe and not exposing themselves to drugs that have shown not to be effective in treating COVID-19.”
The board’s original move to ban the use of hydroxychloroquine to treat COVID-19 came as misinformation continued to spread about it. As recently as this week, Trump has promoted the drug and said he took it as a preventative measure.
McNamee said the board’s initial decision had nothing to do with Trump’s continued endorsement of hydroxychloroquine.
State purchased $600,000 worth of drug in April
This isn’t the first time the state pharmacy board has stepped in to regulate the use of the drug during the pandemic.
In March, the Ohio Board of Pharmacy cracked down on doctors who were hoarding hydroxychloroquine for themselves, family and friends in case it was needed. At that time, the board implemented restrictions that said the drug could be prescribed only for those who had tested positive for COVID-19.
Hydroxychloroquine is typically used to treat malaria, a mosquito-borne illness that causes fever, chills and influenza-like symptoms, according to the federal Centers for Disease Control and Prevention. The drug is also used to treat conditions that cause inflammation, such as lupus and forms of arthritis.
In the early days of the pandemic, the Ohio Department of Health stockpiled the drug in case it turned out to be a good treatment.
The state purchased more than 2 million hydroxychloroquine pills for $602,629 on April 9, Melanie Amato, spokeswoman for the Ohio Department of Health, said via email in June. On April 20, Capital Wholesale Drug in Columbus donated 2 million hydroxychloroquine pills — worth about $680,000 — from drug maker Prasco, which is based in Mason, Ohio.
The amount of pills stockpiled by the state is equivalent to nearly two years’ worth of prescriptions that the state typically would use for its managed-care programs, according to data provided by the federal Centers for Medicare and Medicaid Services.
“The company that donated the 2 million pills is taking them back,” Amato said via email Wednesday. “The ones we purchased we are still looking at options at donating them to foundations that can use them to treat lupus and malaria.”
Contributing: Rick Rouan and Lucas Sullivan, Columbus Dispatch
Follow reporter Max Filby on Twitter: @MaxFilby
At-home testing? FDA opens door to rapid, at-home testing for COVID-19